Similarly, it was also shown that after the uptake of tumour-derived exosomes, DCs induce potent CD8+ T cell-dependent antitumour effects on syngeneic and allogeneic established mouse tumours, highlighting exosomes as a novel source of tumour-rejection antigens for T cell cross priming [222]. The gene discussed is CD8A; the disease is neoplasm.